1. Overview
1.1 About this Report
1.2 Scope of the Report
1.3 Objectives
1.4 Methodology
1.5 Executive Summary
2. Overview of Diagnostic Testing Point of Care
2.1 Point of Care Testing Sites
2.2 Point of Care Market Structure
2.3 New Directions in Clinical IVD Testing
3. POCT and Rapid Testing Market Analysis: Size, Background Analysis, Growth, Share and Competitors
3.1 Global POCT Market
3.2 U.S. POCT Market
3.3 European POCT Market
3.3.1 German POCT Diagnostic Market
3.3.2 U.K. POCT Diagnostic Market
3.3.2.1 U.K. POCT Market Statistics
3.3.2.2 U.K. Competitive Analysis
3.3.2.3 U.K. Market Access
3.3.3 French POCT Diagnostic Market
3.3.4 Italian POCT Diagnostic Market
3.3.5 Spanish POCT Diagnostic Market
3.3.6 Scandinavian POCT Diagnostic Market
3.3.7 Swedish POCT Diagnostic Market
3.3.8 Finnish POCT Diagnostic Market
3.3.9 Norwegian POCT Diagnostic Market
3.3.10 Swiss POCT Diagnostic Market
3.3.11 Dutch POCT Diagnostic Market
3.3.12 Belgian POCT Diagnostic Market
3.3.13 Portuguese POCT Diagnostic Market
3.3.14 Austrian POCT Diagnostic Market
3.3.15 Greek POCT Diagnostic Market
3.3.16 Polish POCT Diagnostic Market
3.3.17 Czech Republic POCT Diagnostic Market
3.3.18 Turkish POCT Diagnostic Market
3.4 Asian POCT Markets
3.4.1 Japanese POCT Diagnostic Market
3.4.2 Indian POCT Diagnostic Market
3.4.3 Chinese POCT Diagnostic Market
3.5 Rest of the World POCT Market
3.5.1 Canadian POCT Diagnostic Market
3.5.2 Brazilian POCT Diagnostic Market
3.5.3 Australian POCT Diagnostic Market
3.6 Overview of Asian Healthcare Market
3.6.1 Singapore
3.6.2 Malaysia
3.6.3 Thailand
3.6.4 Indonesia
3.6.5 Philippines
3.6.6 South Korea
3.6.7 Taiwan
4. POCT Individual Markets
4.1 Glucose Testing
4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors
4.2.1 World Market
4.2.2 U.S. Market
4.2.3 European Market
4.2.4 Alternate Glucose Monitoring Products
4.2.5 HbA1c POCT
4.3 Blood Gas and Electrolytes
4.3.1 Whole Blood Lactate
4.4 Rapid Coagulation Tests
4.4.1 World POCT Coagulation Market
4.4.2 U.S. Coagulation Market
4.4.3 European Coagulation Market
4.4.4 Trends in POCT Coagulation Testing
4.5 Rapid Cardiac Markers
4.5.1 U.S. Market
4.5.2 European Market
4.6 Drugs of Abuse Screening Testing
4.6.1 Acetaminophen
4.6.2 Tricyclic Antidepressants (TCAs)
4.6.3 Other Toxic Drugs
4.6.4 Drug Testing Selectivity
4.6.5 Methaqualone and Phencyclidine (PCP)
4.6.6 Tetrahydrocannabinol
4.6.7 Drug Panels by Toxidromes
4.6.8 Alcohol Testing
4.7 Urine Strips
4.8 Pregnancy Tests
4.9 Fecal Occult Blood
4.10 Hemoglobin Testing
4.11 Miscellaneous Rapid Tests
4.11.1 Estriol
4.11.2 Fetal Fibronectin (fFN)
4.11.3 H. pylori
4.11.4 Vaginal pH and Vaginitis
4.11.5 Bladder Cancer
4.11.6 Fetal Status
4.11.7 Heparin-induced Thrombocytopenia
4.12 Human Immunodeficiency Virus (HIV)
4.13 Cholesterol
4.14 Infectious Disease
4.14.1 Clostridium difficile
4.14.2 Giardia
4.14.3 Salmonella and Campylobacter
4.14.4 Malaria Testing
4.14.5 Influenza Testing
4.14.6 Strep Testing
4.14.7 Chlamydia
4.14.8 Mononucleosis
4.14.9 Rubella
4.14.10 Methicillin-resistant Staphylococcus Aureus (MRSA)
4.14.11 Hepatitis
4.14.12 Gonorrhea
4.14.13 Tuberculosis (TB)
4.14.14 Herpes Simplex Virus Type-2
4.15 Infant Jaundice
4.16 Anthrax
4.17 Rupture of Fetal Membranes (ROM)
4.18 Food Pathogens
4.19 Typhoid
5. POCT: Reagents and Equipment
5.1 Blood Glucose Monitoring
5.1.1 LifeScan
5.1.2 Roche Accu-Chek
5.1.3 Siemens Healthcare Diagnostics
5.1.4 Cholestech (Acquired by Inverness Medical Innovations)
5.1.5 Abbott Diabetes Care
5.1.6 International Technidyne Corporation
5.1.7 HemoCue
5.1.8 Stanbio/GDS Technology
5.1.9 Disetronic Medical Systems
5.1.10 Medtronic MiniMed
5.1.11 Abaxis, Inc.
5.1.12 Arkray
5.1.13 Nova Bio
5.1.14 Accurex (India)
5.1.15 Axis-Shield
5.1.16 Home Diagnostics, Inc.
5.1.17 Medisys/Hypoguard
5.1.18 Diametrics Medical
5.1.19 Metrika
5.1.20 Nova Biomedical
5.1.21 DexCom, Inc.
5.1.22 Bayer
5.1.23 Biosite
5.2 Blood Gas and Electrolytes
5.2.1 Roche Corporation
5.2.2 TechnoMedica
5.2.3 Siemens Healthcare Diagnostics
5.2.4 Instrumentation Laboratory
5.2.5 Nova Biomedical
5.2.6 Radiometer
5.2.7 Abbott Laboratories
5.2.8 Span Diagnostics
5.2.9 Avox Systems
5.2.10 ITC
5.2.11 OPTImedical
5.3 Rapid Coagulation Tests
5.3.1 POC Coagulation Instrument Description
5.3.1.1 Roche Diagnostics Corp.
5.3.1.2 Abbott Laboratories
5.3.1.3 International Technidyne Corporation
5.3.1.4 Medtronic
5.3.1.5 HemoSense (Inverness)
5.3.1.6 Helena Laboratories Point of Care
5.3.1.7 Sienco, Inc.
5.3.1.8 Accumetrics
5.3.2 Connectivity Issues
5.3.3 Cost Benefits
5.3.4 Quality Control Issues
5.3.5 Certification for Point of Care Coagulation Devices
5.4 Rapid Cardiac Markers
5.4.1 Nanogen
5.4.2 Biosite Diagnostics (Inverness)
5.4.3 Roche Diagnostics
5.4.4 Ani Biotech
5.4.5 Response Biomedical Corporation
5.4.6 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics, Diagnostic Products Corporation, and Dade Behring)
5.4.7 Lab21 Ltd.
5.4.8 Abbott Laboratories
5.4.9 LifeSign (Princeton BioMediTech Corp.)
5.4.10 Mitsubishi Kagaku Iatron
5.5 Rapid Drugs of Abuse
5.5.1 Biosite Diagnostics (now a brand of Inverness Medical Innovations)
5.5.2 Abbott Diagnostics
5.5.3 Roche Diagnostics
5.5.4 BioScan Screening Systems, Inc.
5.5.5 American Bio Medica Corp.
5.5.6 Phamatech, Inc.
5.5.7 Worldwide Medical
5.5.8 OraSure
5.5.9 LifePoint
5.5.10 Avitar, Inc.
5.5.11 Cozart Biosciences
5.5.12 Pathtech
5.5.13 Alfa Scientific Designs, Inc.
5.5.14 TCPI, Inc.
5.5.15 Roche
5.5.16 Siemens Corporation
5.5.17 Diagnostic Chemical Ltd.
5.5.18 Quidel
5.5.19 HemoCue (Quest)
5.5.20 Biophor Diagnostics
5.6 Rapid Pregnancy and Fertility Tests
5.7 Fecal Occult Blood
5.7.1 Helena Laboratories
5.7.2 Biomerica
5.7.3 Beckman Coulter
5.7.4 Worldwide Medical
5.7.5 Aerscher Diagnostics
5.7.6 Enterix
5.7.7 Medix Biochemica
5.7.8 Orion Diagnostica
5.8 Hemoglobin Testing
5.8.1 Wampole Laboratories
5.8.2 HemoCue, Inc.
5.8.3 Stanbio/GDS Technology
5.9 Miscellaneous Rapid Tests
5.9.1 Triage C. difficile Panel
5.9.2 Ketoacids
5.9.3 Acetaminophen
5.9.4 Estriol
5.9.5 H. pylori
5.9.6 Vaginal Fluid pH and Vaginitis
5.9.7 Prostate-specific Antigen (PSA)
5.9.8 Bladder Cancer
5.9.9 Other Rapid Cancer Tests
5.9.10 Fetal Status (PROM)
5.9.11 Osteoporosis
5.9.12 Hemodynamic Monitoring
5.9.13 Heparin-induced Thrombocytopenia
5.10 HIV
5.10.1 Whole Blood, Serum or Plasma-based HIV Tests
5.10.1.1 Bio-Rad Laboratories
5.10.1.2 Orgenics (wholly-owned by Inverness Medical Innovations)
5.10.1.3 StatSure Diagnostic Systems
5.10.1.4 Trinity Biotech
5.10.1.5 Savyon Diagnostics
5.10.1.6 MedPharm
5.10.1.7 American Bio Medica Corp.
5.10.1.8 Chembio Diagnostics
5.10.1.9 OraSure Technologies
5.10.1.10 Inverness
5.10.2 Saliva-based HIV Tests
5.10.2.1 OraSure Collection Device
5.10.2.2 SureStat
5.10.3 Urine-based HIV Tests
5.10.3.1 MedMira Laboratories, Inc.
5.10.3.2 Medical Services International, Inc.
5.10.3.3 Maxim Biomedical
5.10.3.4 Wampole Laboratories
5.11 Cholesterol
5.11.1 Cholestech (now a brand of Inverness Medical Innovations)
5.11.2 Actimed Laboratories
5.11.3 StatSite Meter
5.11.4 Polymer Technology Systems
5.11.5 PreMD, Inc. (f/k/a International Medical Innovations, Inc. [IMI])
5.11.6 Abaxis, Inc.
5.12 Infectious Disease
5.12.1 C. difficile
5.12.2 Giardia
5.12.3 Dengue Fever
5.12.4 Malaria Testing
5.12.5 Rapid Influenza Testing
5.12.6 Streptococcus Testing
5.12.7 Chlamydia
5.12.8 Mononucleosis
5.12.9 Rubella
5.12.10 Staphylococcus Aureus and MRSA
5.12.11 Hepatitis
5.12.12 E. Coli O157
5.12.13 Gonorrhea Testing
5.12.14 Smallpox
5.12.15 SARS
5.12.16 Rabies
5.12.17 Tuberculosis
5.12.18 Avian Flu
5.12.19 West Nile Virus
5.12.20 Herpes Simplex Virus Type-2
5.13 Infant Jaundice
5.14 Anthrax
5.15 Homeland Defense (Plague and Tularemia)
5.16 BSE (Mad Cow Disease)
5.17 Tuberculosis
5.18 Typhoid
5.19 Avian Flu
5.20 Food Pathogens (Salmonella, Listeria, Campylobacter)
5.21 Ruptured Fetal Membranes (ROM)
6. POCT: Growth Regulators
6.1 Moderators of Growth
6.2 Personnel Acceptance
6.3 Key People for POCT
6.4 Information Management Issues
6.4.1 Elements of Information Management for POCT: Information Processing Capabilities
6.4.2 Data Mining
6.4.3 Middleware
6.4.4 Web Portals
6.4.5 POCT-1A Standard
6.5 Key Elements for POCT
6.6 POCT and Reimbursement
6.7 Effectiveness of Clinical Outcomes
6.8 Rapid Near-Patient Testing in Hospitals
6.9 Satellite Facilities
6.10 Regionalization of Laboratory Care
6.11 Requirements for POCT
6.12 Locations of Point of Care for Patient Care
6.13 Benefits of POCT
6.14 Cost Elements of POCT
6.15 Necessary Functions in POCT
6.16 TAT for POCT
6.17 Clinical Laboratory Improvement Amendments (CLIA)
6.18 Sexually-Transmitted Diseases in Underdeveloped Countries
7. Business Trends in the Point of Care Sector
7.1 Sector Consolidation
7.2 Diagnostic Testing Growth Trends
7.3 Acquisition, License Agreements, Internal Development and Partnerships
7.4 Product Testing Depth in POCT
7.5 Government Regulation
7.5.1 U.S. Regulation
7.5.1.1 Importing Medical Devices into the U.S.
7.5.1.2 Exporting Medical Devices from the U.S.
7.5.2 U.K. Regulation
7.5.3 E.U. Regulation
7.5.3.1 French Regulation
7.5.4 Japanese Regulation
7.5.5 Korean Regulation
7.6 Increased Market Penetration
7.7 Costs of Doing Business in Europe
7.8 Drivers of European Diagnostics Testing
7.9 European Reimbursement Practices
7.10 Cost Containment in Europe
8. Technology Platform Innovations in POCT
8.1 Sensor Systems for Diagnostic Applications
8.2 Glucose Measurements
8.3 Glucose Test Methods
8.4 Cholesterol Testing
8.5 The New Paradigm
8.6 Consolidated Workstations and Modularity
8.7 Automation and Robotics in the Clinical Laboratory
8.8 Laboratory Information Systems (LIS)
8.8.1 NOVIUS Lab
8.9 Biosensor Technology
8.10 Nanogen Third Generation Point of Care Analyzer
8.11 Quidel MChip
9. Data Management and Connectivity
9.1 Wireless LANs
9.2 Connectivity Platforms
9.2.1 DataLink Data Management System
9.2.2 RALS-Plus
9.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite
9.2.2.2 Siemens Diagnostics Rapidpoint® Coag
9.2.2.3 Radiometer
9.2.2.4 HemoCue's DM Hemoglobin
9.2.2.5 Roche Diagnostics
9.2.3 BD.id
9.2.4 Medical Implant Communications Service (MICS)
9.3 Advantages of POCT Connectivity
9.3.1 Cost Benefit of POCT and IT Connectivity
9.3.2 Hospital Network Issues
10. Corporate Profiles
10.1 Abaxis, Inc.
10.2 Abbott Diagnostics
10.3 Accumetrics, Inc.
10.4 Accurex Biomedical, Pvt. Ltd.
10.5 Akers Biosciences, Inc.
10.6 Alfa Scientific Design, Inc.
10.7 Ambri Ltd.
10.8 American Bio Medica Corporation
10.9 Ani Biotech Oy Ltd.
10.10 Apogent Technologies
10.11 Ark Therapeutics
10.12 Arkray, Inc.
10.13 Atlas Genetics
10.14 Atonomics
10.15 Avitar, Inc.
10.16 Augurix Diagnostics Ltd.
10.17 Axis-Shield
10.18 Beckman Coulter, Inc.
10.19 Binax Corporation
10.20 Biomerica, Inc.
10.21 bioMérieux Vitek, Inc.
10.22 BioScan Screening Systems, Inc.
10.23 Biosite Diagnostics
10.24 BioStar, Inc.
10.25 British Biocell Holdings
10.26 Caliper Life Sciences
10.27 Calypte Biomedical Corporation
10.28 Chembio Diagnostics, Inc.
10.29 Cholestech
10.30 Chongqing Sungene Pharmaceutical Co., Ltd.
10.31 CompuCyte Corporation
10.32 Cortech Diagnostics Ltd. (now Kent International Holdings)
10.33 Cozart Biosciences Ltd.
10.34 Cygnus Therapeutic Systems
10.35 Cytogen Corporation
10.36 DexCom, Inc.
10.37 Daiichi Sankyo Group
10.38 Denka Seiken Co., Ltd.
10.39 Diagnostic Chemicals Ltd.
10.40 Enigma Diagnostics Ltd.
10.41 Focus Diagnostics, Inc.
10.42 GDS Technology
10.43 GenBio
10.44 Genzyme Diagnostics
10.45 Grant Life Sciences, Inc.
10.46 Gryphus Diagnostics, LLC
10.47 Helena Laboratories
10.48 Hema Diagnostic Systems, LLC
10.49 Hemocue, Inc.
10.50 Home Access Health Corp.
10.51 ImmunoScience, Inc.
10.52 Instrumentation Laboratory
10.53 International Medical Innovations
10.54 Inverness Medical Innovations, Inc.
10.55 Johnson & Johnson
10.56 Kyowa Medex Co., Ltd.
10.57 LifeAssays
10.58 LifePoint, Inc.
10.59 LifeScan Corporation
10.60 Lifestream Technologies
10.61 LXN Corp. (Inverness Medical Technologies)
10.62 Matritech
10.63 Medical Services International, Inc.
10.64 MediSense, Inc.
10.65 Medisys
10.66 Medix Biochemica
10.67 MedMira Laboratories
10.68 Meretek Corporation
10.69 Meridian Bioscience
10.70 MiniMed, Inc.
10.71 Mitsubishi Chemical USA, Inc.
10.72 Mitsubishi Kagaku Iatron
10.73 Nanogen
10.74 New Horizons Diagnostics
10.75 Nova Biomedical
10.76 OraSure Technologies, Inc.
10.77 Orgenics
10.78 Orion Diagnostica
10.79 PanBio Ltd.
10.80 Phamatech, Inc.
10.81 Polymedco, Inc.
10.82 Polymer Technology Systems, Inc.
10.83 Princeton BioMeditech Corporation
10.84 Quest Diagnostics, Inc.
10.85 Quidel Corporation
10.86 Radiometer
10.87 Response Biomedical Corp.
10.88 Roche Diagnostics
10.89 Royal Philips Electronics
10.90 Savyon Diagnostics
10.91 Selfcare, Inc.
10.92 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech)
10.93 Shionogi & Co., Ltd.
10.94 Siemens Corporation
10.95 SpectRx, Inc.
10.96 Spectral Diagnostics
10.97 StatSure Diagnostic Systems
10.98 Strategic Diagnostics, Inc.
10.99 Sun Biomedical Laboratories, Inc.
10.100 Thoratec/International Technidyne Corporation
10.101 Transmedica International, Inc.
10.102 Trinity Biotech
10.103 Väsamed, Inc.
10.104 Venkateshwara Hatcheries Pvt. Ltd.
11. POCT Sector Trends and Forecasts
11.1 Home Care Analysis as Part of Near-Patient Testing
11.2 Non-Traditional Collection for POCT
11.3 New Systems for Critical Care and Near-Patient Testing
11.4 Utility of Near-Patient Testing in Critical Care Settings
11.5 Physician's Office Market
11.6 Information Management Advances
11.7 Test-Ordering Patterns and Demand for POCT
11.8 Demand for Emergency Department Services
11.9 Move Away from Central Laboratory
11.10 Healthcare Cost Controls
11.11 M&A in POCT
11.12 Competition for Services
11.13 Drivers of POCT
11.14 Confluence of New Technology
11.15 Difficulties of Design for Point of Care Products
11.16 European Hospital Structure
11.17 The Biggest New Opportunities in POCT
12. Corporate Directory
INDEX OF FIGURES
Figure 3.1: Blood Tests Ordered in Emergency Department Visits
Figure 3.2: Worldwide Distribution of IVD Testing, 2008
Figure 3.3: Global POCT Share of Total IVD Testing Market, 2007
Figure 4.1: U.S. POCT Share of Glucose Testing Market, 2008
Figure 4.2: Number of HbA1c Tests Performed Globally as POCT, 1991-2006
Figure 4.3: Total Spending on Healthcare in the U.S., 1960-2007
Figure 4.4: International Per Capita Healthcare Spending Per Country, 2006
Figure 5.1: Global POCT Share of HIV Testing Market, 2008
Figure 6.1: Annual Rate of Emergency Room Visits by Primary Expected Source of Payment
INDEX OF TABLES
Table 2.1: Percentage of POCT Performed in Selected Hospitals
Table 2.2: POCT Procedural Advantages for Hospital Testing
Table 2.3: POCT Trends
Table 2.4: Professional POCT Compared to Home Testing
Table 2.5: Drivers for Integrating POCT into Hospital Routines
Table 3.1: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2008
Table 3.2: Number of Point of Care Tests in the U.S., 2000-2012
Table 3.3: Global Clinical Laboratory Market Sales, 1998-2011
Table 3.4: Overall IVD Testing Market Worldwide, 2007
Table 3.5: Worldwide Distribution of IVD Testing, 2008
Table 3.6: Top 12 Country IVD Testing Markets, 2007
Table 3.7: Top 13 Diagnostic Companies Worldwide, 2007
Table 3.8: Global Point of Care Revenues, 2005-2012
Table 3.9: Worldwide POCT Market Size by Geographic Location, 2005-2012
Table 3.10: Worldwide Distribution of POCT, 2008
Table 3.11: Worldwide Clinical Diagnostic POCT and Rapid Test Market Segments, 2007
Table 3.12: Worldwide POCT by Performance Location, 2008
Table 3.13: Largest POCT Diagnostic Companies Worldwide, 2007
Table 3.14: U.S. Clinical Laboratory Testing Market, 2003-2012
Table 3.15: U.S. Clinical Laboratory Diagnostic Test Market Segments by Location of Analysis, 2008
Table 3.16: U.S. POCT Market, 2000-2012
Table 3.17: U.S. POCT by Performance Location, 2008
Table 3.18: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments, 2007
Table 3.19: European Clinical Laboratory Testing IVD Reagents and Instruments Market in Dollars, 2000-2012
Table 3.20: European Clinical Laboratory Testing IVD Reagents and Instruments Market in Euros, 2000-2012
Table 3.21: European Clinical Laboratory Testing Diagnostics by Country Market Estimates, 2007
Table 3.22: European Rapid POCT by Country Market Estimates, 2008
Table 3.23: Regional Comparison of Healthcare Spending for IVD for Eastern Europe
Table 3.24: European POCT Market, 2005-2012
Table 3.25: Top 12 Country IVD and POCT Markets, 2007
Table 3.26: German Clinical Laboratory Testing Diagnostics Products Market Sales, 2003-2012
Table 3.27: German POCT Diagnostics Products Market Sales, 2003-2012
Table 3.28: German Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.29: U.K. Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.30: U.K. POCT Diagnostics Products Market Sales, 2006-2012
Table 3.31: U.K. Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.32: Major U.K. IVD Manufacturers
Table 3.33: U.S. IVD Manufacturers Doing Business in the U.K.
Table 3.34: Other European Companies that Manufacture IVD Products in the U.K.
Table 3.35: French Clinical IVD Testing Diagnostics Products Market Sales, 2003-2012
Table 3.36: French POCT Diagnostics Products Market Sales, 2005-2012
Table 3.37: French Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.38: Italian Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.39: Italian POCT Diagnostics Products Market Sales, 2005-2012
Table 3.40: Italian Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.41: Spanish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.42: Spanish Clinical Diagnostic Rapid Test Market Segments, 2007
Table 3.43: Spanish POCT Diagnostics Products Market Sales, 2005-2012
Table 3.44: Scandinavian POCT Diagnostics Products Market Sales, 2000-2012
Table 3.45: Swedish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.46: Swedish POCT Diagnostics Products Market Sales, 2005-2012
Table 3.47: Finnish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.48: Finnish POCT Diagnostics Products Market Sales, 2005-2012
Table 3.49: Norwegian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.50: Norwegian POCT Diagnostics Products Market Sales, 2005-2012
Table 3.51: Swiss Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.52: Swiss POCT Diagnostics Products Market Sales, 2005-2012
Table 3.53: Dutch Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.54: Dutch POCT Diagnostics Products Market Sales, 2005-2012
Table 3.55: Belgian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.56: Belgian POCT Diagnostics Products Market Sales, 2005-2012
Table 3.57: Portuguese Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.58: Portuguese POCT Diagnostics Products Market Sales, 2005-2012
Table 3.59: Austrian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.60: Austrian POCT Diagnostics Products Market Sales, 2005-2012
Table 3.61: Greek Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.62: Greek POCT Diagnostics Products Market Sales, 2005-2012
Table 3.63: Polish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
Table 3.64: Polish POCT Diagnostics Products Market Sales, 2005-2012
Table 3.65: Czech Clinical Laboratory Diagnostics Products Market Sales, 2004-2012
Table 3.66: Czech POCT Diagnostics Products Market Sales, 2005-2012
Table 3.67: Turkish POCT Market, 2000-2012
Table 3.68: Japanese POCT Market, 2000-2012
Table 3.69: Japanese Population and Aging Demographics Forecast, 2000-2050
Table 3.70: Indian IVD Market for Instruments and Reagents, 2004-2012
Table 3.71: Number of Automated Clinical Labs in India, 2004-2012
Table 3.72: Indian IVD Market, 2007
Table 3.73: Indian POCT Diagnostics Products Market Sales, 2000-2012
Table 3.74: Chinese IVD Market, 2006-2012
Table 3.75: Number of Automated Clinical Labs in China, 2004-2012
Table 3.76: Chinese IVD Market, 2007
Table 3.77: Chinese POCT Diagnostics Products Market Sales, 2000-2012
Table 3.78: Rest of the World POCT Market, 2000-2012
Table 3.79: Canadian POCT Market, 2000-2012
Table 3.80: Brazilian POCT Market, 2000-2012
Table 3.81: Australian POCT Market, 2000-2012
Table 4.1: World Market Share of Point of Care Glucose Monitoring Marketers
Table 4.2: Global Population of Persons with Diabetes, 1995 and 2025
Table 4.3: Professional Glucose Testing Market for POCT Worldwide, 2001-2012
Table 4.4: U.S. Point of Care Glucose Testing Market, 1997-2012
Table 4.5: Manufacturer Market Share U.S. POCT Market, 2008
Table 4.6: Rapid Testing U.S. Market Share for Blood Glucose Testing Segment
Table 4.7: HbA1c Testing Market for POCT Worldwide, 2006-2012
Table 4.8: Critical Care Blood Gas Testing Market for POCT Worldwide, 2006-2012
Table 4.9: Blood Gas and Electrolyte Market for POCT in the U.S., 2001-2012
Table 4.10: Location Market Share of Critical Care Blood Gas Testing, 1990 and 2008
Table 4.11: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes Market, 2007
Table 4.12: Hospital Locations of Point of Care Coagulation Testing
Table 4.13: Drivers for Point of Care Coagulation Testing
Table 4.14: Barriers for Point of Care Coagulation Testing
Table 4.15: Coagulation Testing Market for POCT Worldwide, 2006-2012
Table 4.16: Handheld Coagulation Testing Market for POCT Worldwide, 2006-2012
Table 4.17: Coagulation Market for POCT in the U.S., 2001-2012
Table 4.18: Point of Care Prothrombin Market for POCT in the U.S., 2000-2008
Table 4.19: Cardiac Marker Market for POCT in the U.S., 2001-2012
Table 4.20: Cardiac Marker Market for POCT Worldwide, 2001-2012
Table 4.21: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2007
Table 4.22: Cardiac Marker Market for POCT in Europe, 2001-2011
Table 4.23: Drugs of Abuse Testing Market for POCT Worldwide, 2006-2012
Table 4.24: U.S. Point of Care Drugs of Abuse Testing Market, 2006-2012
Table 4.25: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department
Table 4.26: Stat Urine Testing Drug Recommendations
Table 4.27: Device Specifications for POCT Breath Alcohol Analysis
Table 4.28: Global Point of Care Urine Test Strip Testing Market, 2001-2008
Table 4.29: Global Point of Care Urine Test Strip POCT Testing Market, 2006-2012
Table 4.30: U.S. Point of Care Urine Test Strip Testing Market, 2001-2011
Table 4.31: U.S. Point of Care Urine Test Strip Testing Market Share
Table 4.32: Medicare Fee Schedule for Urine Chemistry Testing, 2003
Table 4.33: Pregnancy Testing Market for POCT Worldwide, 2006-2012
Table 4.34: U.S. Point of Care Pregnancy Testing Market, 2001-2012
Table 4.35: International Point of Care Pregnancy Testing Markets, 2001-2007
Table 4.36: U.S. Market Share for Rapid Point of Care Pregnancy Tests
Table 4.37: Hemoglobin Testing Market for POCT Worldwide, 2006-2012
Table 4.38: Drivers of Demand for HIV Testing
Table 4.39: Worldwide POCT Market for HIV, 2001-2012
Table 4.40: U.S. POCT Market for HIV, 2001-2012
Table 4.41: Countries with the Highest Prevalence of HIV/AIDS
Table 4.42: FDA-approved Rapid HIV Antibody Screening Tests
Table 4.43: OraSure OraQuick Rapid HIV Test Revenues, 2008
Table 4.44: Cholesterol Testing Market for POCT Worldwide, 2006-2012
Table 4.45: Infectious Disease Testing Market for POCT Worldwide, 2006-2012
Table 4.46: Salmonella Testing Market, 2002-2007
Table 4.47: Worldwide Point of Care Influenza Testing Market, 2002-2007
Table 4.48: U.S. Point of Care Influenza Testing Market, 2002-2007
Table 4.49: International Point of Care Influenza Testing Markets, 2002-2007
Table 4.50: U.S. Market for Rapid Point of Care Influenza Tests, 2007
Table 4.51: Worldwide Point of Care Strep A Testing Market, 2002-2007
Table 4.52: U.S. Point of Care Strep A Testing Market, 2002-2007
Table 4.53: International Point of Care Strep A Testing Markets, 2002-2007
Table 4.54: U.S. Market for Rapid Point of Care for Group A Strep Tests
Table 4.55: Global Market for Chlamydia Diagnostic Testing, 2000-2009
Table 4.56: U.S. Market for Chlamydia Diagnostic Testing, 2000-2009
Table 4.57: U.S. Market for MRSA Rapid Testing, 2006-2013
Table 4.58: Global Market for Gonorrhea Diagnostic Testing, 2000-2009
Table 4.59: Global Market for TB Diagnostic Testing, 2000-2008
Table 4.60: U.S. Anthrax Test Market
Table 5.1: Largest U.S. POCT Coagulation Diagnostic Testing Companies, 2008
Table 5.2: Actalyke XL
Table 5.3: Actalyke Mini
Table 5.4: Drug Test Sensitivity Cut-Off Levels Set by NIDA, WHO and SAMHSA for Drugs of Abuse
Table 5.5: Major Competitors in the Drugs of Abuse Testing Market Segment
Table 5.6: Major Competitors in the Drugs of Abuse Oral Testing Market Segment
Table 5.7: Major Competitors in the Drugs of Abuse Urine Testing Market Segment
Table 5.8: Major Competitors in the Drugs of Abuse Saliva Testing Market Segment
Table 5.9: Siemens Urinalysis Near-Patient Devices
Table 5.10: ColoCARE Fecal Occult Blood Test
Table 5.11: Competitive Factors Related to HIV Tests
Table 5.12: Largest POCT Diagnostic Companies Worldwide, 2008
Table 5.13: Type of Hepatitis Test: Lateral Flow
Table 5.14: Flow-through
Table 5.15: Agglutination
Table 5.16: Immunoblot
Table 5.17: AmniSure
Table 6.1: Access Points
Table 6.2: Desktop Adapters-Four Computers
Table 6.3: Desktop Adapters-One Computer
Table 6.4: PCMCIA Adapters
Table 6.5: POCT1-Compliant Connectivity Point of Care Instruments
Table 6.6: POCT Clinical Outcomes in Diabetic Ketoacidosis
Table 6.7: POCT Clinical Outcomes in Arterial Blood Gas Measurements
Table 6.8: POCT in Three Hospitals-Cost Analysis with Labor Included
Table 6.9: POCT versus Central Lab-Cost Analysis for Glucose Testing
Table 6.10: Financial Comparison for Moderate and Waived CLIA Labs
Table 7.1: Key Changes in IVD Business Structure
Table 7.2: Business Trends in POCT
Table 7.3: Key Players Bring Business Developments to Point of Care Diagnostic Testing
Table 8.1: Normal Glucose Values-Fasting State
Table 9.1: Applications for Wireless LAN Technology
Table 9.2: Customized Reports Must Support CAP and JCAHO Requirements
Table 9.3: RALS-Plus Point of Care Market Share
Table 9.4: Applications of RALS Connectivity with POCT Devices
Table 10.1: Abaxis Blood Analysis Diagnostic Tests
Table 10.2: Reagent Discs Offered with the Piccolo Chemistry Analyzers
Table 10.3: Products Marketed by Abbott in the Diagnostic Market
Table 10.4: Inverness Brands
Table 10.5: Orasure's Products
Table 10.6: Quidel Product Sales Distribution and Sales, 2008
Table 11.1: Improvements in Achieving ED Operational Efficiency Using POCT
Table 11.2: Test Menu and TAT for ED
Table 11.3: Top Reasons Why Point of Care Cardiac Marker Testing is Implemented in the ED
Table 11.4: Key Areas and Metrics that Hospitals Measure to Assess Efficiency of ED
Table 11.5: Estimates of Patient Costs by DRG
